



Aratana Therapeutics

Pet project

Aratana's acquisition of the privately held Vet Therapeutics for a total of \$43m upfront and \$5m milestone payments brought the company closer to commercialising its own products, enriched its pipeline and expanded its therapeutic coverage. We believe this transaction is not only strategically sound, but also financially attractive to Aratana, making this unique recent IPO company's investment thesis more appealing.

Aratana to acquire Vet Therapeutics

Aratana has decided to acquire privately held Vet Therapeutics for a total of \$43m upfront (including \$30m in cash, \$3m in sellers' debt and \$10m worth of stocks (625,000 shares at \$16.00) and \$5m milestone payments. Vet Therapeutics develops canine versions of human monoclonal antibodies (mAbs) for cancer treatments, with one (canine anti-CD20 mAb, Rituxan, for B-lymphoma) approved and another (canine anti-CD52, Campath, for T-lymphoma) conditionally approved.

Earlier commercialisation and broader coverage

With Vet Therapeutics, Aratana now claims both small molecule and large biologic product offerings. Products from Vet Therapeutics enable Aratana to reach commercialisation stage earlier (2015 vs 2016 previously), which could benefit later product launches (AT-001 and AT-002 in 2016). Vet Therapeutic's cancer focus also expands Aratana's therapeutic coverage, which previously included pain and appetite stimulation.

Unique business model/risk

Aratana's focus on pet therapeutics separates it from most biotech companies. Its strategy of licensing drugs already tested in animals from pharma and biotech companies for use in companion animals carries fewer clinical risks than most pharma and biotech drugs, and thus may offer better returns for investors.

Valuation: EV of \$536m seems reasonable

Aratana's EV, at c \$536m, largely reflects the value of the three drugs in development and two canine mAbs from Vet Therapeutics. In the near term, top-line results from dose-ranging studies of AT-001, if positive, could increase the firm's value.


| Consensus estimates | | | | | | |
|---------------------|------------------|--------------|-------------|-------------|------------|--------------|
| Year end | Revenue (\$m) | PBT (\$m) | EPS (\$) | DPS (\$) | P/E (x) | Yield (%) |
| 12/11 | 0 | (3.46) | (15.42) | N/A | N/A | N/A |
| 12/12 | 0 | (11.64) | (34.54) | N/A | N/A | N/A |
| 12/13e | 0 | (18.5) | (0.98) | N/A | N/A | N/A |
| 12/14e | 2 | (28.4) | (1.08) | N/A | N/A | N/A |

Source: Bloomberg

Pharma & biotech

23 October 2013

21 9m



Business description

Shares in issue

Aratana is a biopharmaceutical company developing and commercialising prescription medicines for cats and dogs. Its lead drug candidates include AT-001 for pain, AT-002 for appetite stimulation, AT-003 for post-operative pain and several canine specific antibodies for cancer via acquisition of Vet Therapeutics.

Bull

- Attractive, de-risked business model.
- Short development timeline.
- Near-term (November 2013) catalysts (AT-001 trial data).

Bear

- Market dominated by a few large players.
- Innovation dependent on others.
- Year-end net cash \$35-45m.

Analysts

Jason Zhang PhD +1 646 653 7027 Robin Davison +44 (0)20 3077 5737

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.isa.gov.uk/register/firm/BasicDetails.do?sid=181584). Edison Investment Research (N2) Limited (Edison N2) is the New Zealand subsidiary of Edison. NZ is registered on the New Zealand Financial Services only. Edison Investment Research Inc. (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [4608589] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible drien and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is fis not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand residner professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. Edison has a restrictive p